O endereço abaixo não existe na globo.com The Brazil Technology Development Center will be built in Indaiatuba (SP) with opening planned for the end of 2024 a global technology company that provides software and equipment for the agriculture has announced the construction of the Brazil Technology Development Center its first development and testing center for tropical agriculture in the world The company will invest around R$180 million in the project with the aim of promoting synergy between the multiple R&D teams that are dedicated to designing and validating new products and technologies for the main production systems – grain “Aware of the growing global demand for food and understanding the fundamental role that Brazil plays in this context this Center will promote the development of everything that’s applicable to tropical agriculture We’re going to be offering the Brazilian market a faster and more excellent service than we do currently” which will cover an area of 500,000 m² Construction started in November 2023 and the finished building is expected to be delivered by the end of 2024 Around 150 employees will work at the Center in the engineering and R&D areas “The center will allow products to be conceived and tested in Brazil considering all the variables: soil This will ensure that solutions are delivered to local customers more quickly so small medium and large Brazilian producers can work in an even more productive With the setting up of the new Brazil Technology Development Center John Deere expects to reduce the development time for new solutions by up to 40% The company has already launched products with a specific focus on the local market a Brazilian project designed to meet the needs of the country’s sugarcane producers This new Center will make it possible to speed up the delivery of solutions to the Brazilian market and considering its specific needs more and more The company’s Center for Precision Agriculture and Innovation (CAPI) which was set up in 2017 for research into and the development of the very latest trends in technological efficiency for farmers with a focus on the use of hardware and software in precision agriculture will now become an integral part of the new Center in Indaiatuba John Deere has been in Brazil since 1979 when it acquired part of the capital of Schneider Logemann & Cia (SLC) a plant located in Horizontina (RS) that was responsible for producing the first self-propelled harvester in the country and its subsequent investments and expansion in the Brazilian market follow the history of agriculture in the country Among the units the company has inaugurated in Brazil are the Parts Distribution Center for South America and the Precision Agriculture and Innovation Center in Campinas (SP) It has also opened two Construction plants and the Regional Office for Latin America in Indaiatuba (SP) and expanded its plants in Catalão (GO) Montenegro (RS) and Indaiatuba (SP) to manufacture more of its products locally John Deere has also acquired: Auteq Telemática a software and on-board computer company; PLA which specializes in parts and after-sales service for sugarcane harvesters; and Ciber a world leader in paving and road building solutions which was acquired by John Deere in 2017 Now with this new Center the company is underlining the relevance of tropical agriculture as it continues investing in the country both in product development and infrastructure Its combined businesses in the country employ directly more than 9,000 people and produce equipment that is exported to more than 55 countries “We are extremely pleased to be announcing this investment which is in line with our aim of further contributing to the development of the Brazilian market Brazil has an important role to accomplish for the world and John Deere is proud to be part of this history” Press information about John Deere: johndeere@cdicom.com.br www.facebook.com/JohnDeere twitter.com/JohnDeereBrasil http://www.youtube.com/JohnDeereBrasil https://conecta.deere.com.br/ @JohnDeereBrasil on Instagram Liz Dominguez is the senior editor for CGT, reporting on the latest breaking news in the retail and consumer goods space and helping today's business leaders retain the competitive edge in their respective areas.   Brazil locations are being recognized for implementing advanced fourth industrial revolution (4IR) technologies Learn more about Tianjin here and Indaiatuba here The World Economic Forum has been awarding sites since 2018 that are adopting advanced technologies in manufacturing and supply chain operations They maximize efficiency and competitiveness and showcase a model that can be replicated across different industries and geographies.  head of advanced manufacturing and value chain at the World Economic Forum Lighthouses demonstrate how companies can scale advanced tech across manufacturing networks Unilever said in a company blog post that by integrating these technologies it has been able to increase productivity and efficiency respond more quickly to consumer demand shifts better equip its workforce with digital skills and be more mindful of environmental impacts.  added on to Unilever’s Dubai (personal care) and Dapada (home care) factories means the company now has a lighthouse across each one of its business groups “To be named a Lighthouse Factory is one of the world’s most influential awards in the field of advanced manufacturing but also means that we have advantages over our competitors in terms of better products and service,” said Reginaldo Ecclissato Unilever’s chief business operations officer “It will continue to help our business grow with digital-driven rapid response and deliver long-term value.” The company’s Brazil plant — the largest renewable energy soap powder production plant in the world — is the first of Unilever’s factories in Latin America to earn WEF’s recognition. The factory implements digital twins, artificial intelligence and machine learning to predict new processes for laundry powder formulas The company reports this has improved cost efficiency and agility eliminating the need for physical trials and speeding up innovation it has significantly cut down on Unilever’s environmental footprint.  Unilever’s previous process accounted for 80% of the plant’s energy consumption. By switching over to locally sourced biomass for power and implementing these technologies (which improve thermal efficiency) the company has cut down on the plant’s scope 1 emissions by 96% and energy consumption and related costs by more than 50%.  the company is leveraging machine learning to increase the quality of its products and reduce waste by improving sealing for its laundry detergent packs.  By tapping into machine learning, the company no longer relies on manual processes, which in the past was prone to human error due the heavy lift: 600 daily decisions, 13 variables, and constant changes. Unilever says the team can now predict ideal allocations and routes using real-time data in order to reduce distribution costs, and improve inventory and service levels.  Machine learning has also allowed the company to predict optimal times for equipment maintenance and maximize machinery availability.  The company has also heavily invested in its workforce launching a digital training program to upskill employees (as well as more than 70 employees from seven other Unilever factories in the region) Unilever also taps into a network of 35 partners to quickly innovate and prototype The company's Tianjin factory produces the company’s Knorr and Hellmann’s products and is the world’s first lighthouse factory that is dedicated to savory foods — and the company’s third lighthouse in China.   By implementing data analysis and machine learning in this location Unilever has been able to improve its strategies around serving existing and new restaurant customers The technology improves agility in its manufacturing processes allowing Unilever to quickly increase or decrease production depending on shifts in customer orders and demand.  Unilever integrates its planning systems and is able to better translate data to suppliers increasing control over inventory and logistics This has also helped minimize waste and business loss and increase brand penetration in towns and small cities Você está usando um navegador antigo e que não tem suporte a muitas de nossas funcionalidades . Por favor faça a atualizaçãor para uma melhor experiência You can change your cookie settings by turning on or off analytical and third-party cookies right here. You cannot turn-off strictly necessary cookies. You can find out more about cookies aqui. Please note that some features of the website will not work without cookies. BrazilThe 11,200-square-meter facility includes a renovated warehouse that accommodates a significantly larger parts inventory debuted its newly renovated distribution center in Indaiatuba Members of JLG’s leadership teams in Latin America and North America greeted customers as well as members of the community and media for a cocktail reception press conference and stops at key locations in the updated facility “The investment JLG has made in the Indaiatuba distribution center underscores the company’s ongoing commitment to Latin America,” said Tim Morris JLG Industries senior vice president sales market development and customer support – Americas “We are now better positioned to support our customers as they take advantage of the many growth opportunities that are transforming Latin American into such an attractive and important market.” Marco Cardoso JLG Industries vice president of sales and aftermarket “The distribution center also demonstrates JLG’s commitment to Brazil and the local Indaiatuba economy As Brazil prepares to host the 2014 World Cup and 2016 Olympic Games we are anticipating tremendous infrastructure improvements in the region We have increased our workforce in Indaiatuba by 40 percent recruiting local talent and investing $2.9 million in human capital that will support our customers with innovative products and services as they take advantage of the opportunities these improvements present.” Center triples inventory and introduces new technologies The 11,200-square-meter facility includes a renovated warehouse that accommodates a significantly larger parts inventory “JLG is the first company in Brazil to deploy the shuttle order picking solution in a distribution facility,” said Donnell Mata JLG Industries director of product support-Latin America “This cutting-edge technology supports efficient business operations by expediting the picking process and enabling our employees to fill orders at a significantly increased speed our increased parts inventory contributes to improved fill rates for our customers.” improved fill rates mean less downtime on the jobsite “And because JLG can provide more of what our customers need from a single they no longer need to import equipment and parts on their own saving time and the extra costs associated with the importation process Our focus is to provide our customers with a life-cycle solution – a solution that gives them not only the products they need but also the service to support those products in the field.”  JLG Industries director of market development – Latin America adds, “Customers throughout Latin America will also benefit from JLG’s mobile app Online Express allows customers to access direct quotes making it easier for them to do business with JLG It’s just one more way that JLG is reaching out to customers in this region and supporting them with the resources and equipment they need to succeed.” Call centers and training area improve customer service The updated facility also includes two new parts and service call centers which improve customer support and service by providing direct access to JLG to place orders and resolve service issues The center also houses a new training area that will introduce rental and construction companies to JLG products and provide equipment operation and maintenance instruction Those who attended the event also had the opportunity to visit the distribution center’s two shipyards and experience JLG equipment during an equipment rodeo The rodeo spotlighted the SkyTrak 8042 telehandler the Indaiatuba community is also benefitting from JLG’s expanded presence in the area employees at the Brazil Distribution Center helped remodel a children’s shelter in Indaiatuba JLG equipment is helping build two million homes for low-income families across Brazil as part of the Minha Casa With manufacturing facilities in China, the United States, Belgium, Romania, and one in France, and sales and service support across six continents, JLG customers all over the world can secure the right equipment for the jobs at hand. For additional information about JLG products, visit the company website at www.jlg.com. Metrics details Cervical cancer screening in Brazil is opportunistic based on cytology and offered for women aged 25–64 years with low coverage (30%) and 70% of cancer diagnoses done in advanced stages The current study reports 5-year first-round results of a population-based DNA-HPV testing screening program in a Brazilian city which intended to be a model for transition to a more efficient program indicating repetition of a negative test after five years The first-round (October 2017-September 2022) screened 20,551 women by DNA-HPV testing with 58.7% coverage and 99.4% compliance with the program's targeted age range Coverage increases to 77.8% when excluding the ‘pandemic period’ The DNA-HPV testing was 87.2% negative with 6.2% colposcopy referrals and 84.8% colposcopies performed A total of 258 high-grade precursor lesions and 29 cervical cancers (mean age = 41.4 years 41,387 cytology tests from the previous program (2012–2016) detected 36 cervical cancers (mean age = 52.0 years with 67% in advanced stages (p < 0.0001) Organizing cervical cancer screening using DNA-HPV testing demonstrated good coverage and detection of more precancerous lesions and cervical cancers 10 years in advance the World Health Organization (WHO) recommended replacing cytology-based careening with HPV test-based screening we report the 5-year first-round performance of the screening program in terms of detecting precancerous lesions and cervical cancers The first-round coverage was 58.7% (20,551/35,000) lines represent the projected cumulative population coverage for 5 years: 80% coverage (orange line) and 100% coverage (green line) The monthly mean of number HPV tests performed during the COVID-19 pandemic waves in Brazil were 33 tests/month in April-September 2020 and 158 tests/month in January-March 2022) the average tests/month was 396 (November 2019-February 2020) and 320 (April-September 2022) Excluding 17 months related to the ‘pandemic waves period’ the coverage increased to 77.8% (19,144/24,817) The results of the tests used in both screening program (DNA-HPV-based and conventional cytology) are summarized in Table 1 Negative DNA-HPV test results were observed in 87.2% of women (vs 3.5% tested positive for HPV-16 and/or HPV-18 and 9.3% tested positive for one of the 12 other hr-HPVs and performed a reflex cytology Reflex cytology results were negative in seven of each 10 cytology tests who were recommended to return after 12 months to repeat the DNA-HPV test The colposcopy referral rate was 6.2% for DNA-HPV testing a rate that was 4.4 times higher than that of the previous cytology program (1.41% Colposcopy compliance was high in the PREVENTIVO program, with a diagnosis reached in 84.8% (1073/1266) of cases referred for colposcopy. For the cytology program, data were available for only 37.2% (217/584) of the colposcopies indicated (Table 1) the colposcopy referral rate for the same age group was 2.4% (97/4012) with 26 HSIL and no cervical cancer cases detected No significant differences in the proportion of HSIL detection were observed in the DNA-HPV test program for the age groups 25–29 years versus 30–39 years (2.4% vs Considering screening tests performed outside the target age group a total of 122 DNA-HPV tests performed in the 20–24 years age group exhibited a low rate of HSIL detection (3.3% and no HSIL cases were detected in 122 women aged ≥ 65 years the HSIL detection rate in the 20–24 years of age was 0.4% (15/4192) The HSIL detection rate in women aged ≥ 65 years was 0.02% (2/2492) all of which were symptomatic and in an advanced stage (two Stage II A detailed analysis of the cervical cancer cases diagnosed in both programs is shown in Table 3 A total of 29 cases were detected in the DNA-HPV program (mean age 41.4 years) and 36 cases were detected in the cytology program (mean age 52 years Glandular-type cancers accounted for 28% of cases detected in the DNA-HPV test program and 19% of cases detected in the cytology program (p = 0.7369) A total of 83% of cancers detected in the DNA-HPV program were FIGO Stage I and cases with FIGO Stage II-IV predominated in the cytology program The DNA-HPV test detected 62% (18/29) of microinvasive cancers (FIGO Stage IA) compared to only 14% (5/36) detected in the cytology program A review of the status of cancer cases in the DNA-HPV testing program revealed that one 48-year-old woman died 6 months after diagnosis (Squamous cell carcinoma and 10 deaths were recorded in the previous cytology program all of which involved Stage III-IV cancers in women with a mean age of 58 years The 5 year first round of the PREVENTIVO screening program utilizing primary DNA-HPV testing showed high coverage of the target group (25–64 years old) with a higher rate of precancerous lesion detection potentially enabling diagnosis of prevalent cervical cancers as much as 10 years in advance and at an early stage These remarkable results were obtained in a population with access to the opportunistic screening program based on conventional cytology The achievements of the present DNA-HPV test reflect an organized program implementing a more accurate test combined with higher coverage and high proportion of adequate follow-up of women who tested positive the first obstacle to overcome was the culture of annual screening tests in the previous cytology-based program The switch to DNA-HPV testing enabled the implementation of new practices Another advance was the implementation of a single flowchart for women aged 25–29 years and those aged ≥ 30 years Indaiatuba City was chosen because it already had a structured healthcare system in which all care units were networked and a centralized digital system to control entrance into the screening program and monitor follow-up of abnormal test results was developed All healthcare professionals were trained to follow the flowchart and various strategies for providing guidance to patients regarding periodicity and actions to identify candidates for screening were added The present first-round analysis revealed high age compliance and sustained coverage even considering the negative effects of the COVID-19 pandemic The rapid recovery in the number of tests performed after the pandemic suggests well-targeted and well-coordinated action Indaiatuba City performed 11,000 cytology tests annually this achievement was accompanied by 231 cases of LSIL (CIN1) transient lesions The integration of additional tests in the DNA-HPV program could improve discrimination in the future A challenge addressed by the new program was how to manage women in the 25- to 29-years-old group as the recommendation was to begin DNA-HPV testing after the age of 30 years Considering the programmatic issues of maintaining the health structure for cytology screening to a specific subgroup of targeted women such as the difficulty in controlling actions on the front and the possibility of carrying out two tests leading to a risk of confusion and loss of economic performance of the program it was decided to remove all cytology testing from primary healthcare facilities and offer DNA-HPV tests to women 25–29 years old for the low specificity of the HPV test in women < 30 years old the 25–29 years age group had more colposcopy referrals but comparison with the cytology program revealed an odds ratio similar to the 30–39 years age group A total of 2.4% of detected lesions (65/2742) were HSIL (CIN2/3) in the 25–29 years age group similar to the 30–39 years age group (1.9% the DNA-HPV program detected two cancer cases (both microinvasive) in the younger group The present study describes a path to transition programs tested under real-world conditions within the Brazilian public health system a reduction in colposcopy referrals and cervical cancer detection are expected there were seven cases reported for the previous program with cytology Although a DNA-HPV test at the exit of the screening was offered to women aged 65 or older there were no significant lesions detected in 122 women tested a campaign is planned to call and test older women aiming at the detection of cancers prevalent in this group The main strength of this demonstration study is that it describes the steps to transition the screening programs to a more-targeted organization under real-world scenarios within the Brazilian public health system The results obtained through the application of a single flowchart are striking and support the modernization of the current Brazilian program The results could serve as a reference for other countries in similar situations Although the PREVENTIVO program was open to all women of target age the main limitation was the inability to include users of private clinics which encompasses approximately 50% of the population replicating this program will require a greater investment in the acquisition of HPV tests and establishing consistent and accessible population records on dedicated digital platforms to successfully run and manage the program Some data from the previous cytology program may be less reliable which is expected considering its limited organization and the results presented were used for reference only and should thus be considered with caution the implementation of an organized screening program for cervical cancer prevention via DNA-HPV testing in a Brazilian city demonstrated good coverage overcoming the effects of the COVID-19 pandemic and achieving high age and colposcopy compliance in a real-world scenario The program provided notably increased precancerous lesions detection potentially enabling cervical cancer diagnosis 10 years in advance with a high proportion of cancers detected at an early stage The program results should be reproducible in similar settings in which the burden of this preventable cancer is high This population-based demonstration study evaluated the “PREVENTIVO” program (PREvention of HPV Viruses in ENTire Indaiatuba by Vaccination and Organization of the screening) cervical cancer screening program which was initiated in October 2017 in Indaiatuba City The program targeted women 25–64 years old for screening via primary DNA-HPV testing the inclusion criteria considered women in the targeted age group (women over 64 years were permitted for a single exit test by personal request) who have started sexual activity and are physically well enough to undergo a pelvic exam The entrance should be postponed if any of the following conditions are met: 40 days postpartum period and having undergone the last cervical cytology in the last 12 months The exclusion criteria considered women who have already undergone DNA-HPV testing for different medical purposes except screening with a previous diagnosis of the cervical lesion followed in specialized clinics and women who underwent a total hysterectomy the Brazilian National Vaccination Program offers vaccination free of charge to girls 9–14 years old will reach the screening age in 2025; therefore we assumed that nearly 100% of women screened in the new program were unvaccinated we considered the 6-month period from November 2019 to February 2020 as ‘before’ the pandemic and the 6-month period of April to September 2022 as ‘after’ the pandemic The first-round evaluation focused on coverage The program's performance among women 25–29 years old was also evaluated The Cobas HPV test simultaneously provides individual results regarding the highest-risk genotypes (HPV-16 and HPV-18) and aggregates results for the 12 other hr-HPV genotypes (types 31 the following clinical procedures were followed based on DNA-HPV test results: Negative: return after 5 years to repeat the test; Positive HPV-16 and/or HPV-18 test: referral for colposcopy the woman should return after 12 months to repeat the DNA-HPV test The study considered data for women screened during the 60-month first round of the new program All data were retrieved and generated by the health information system The research team had access to all data and participated in quality control surveillance of the program Some women had more than one cytology tests during the period and in cases in which there was more than one abnormal cytology test indicating colposcopy (ASC-H Colposcopy was indicated if a cytology result was ASC-US in two consecutive tests conducted over a 6- to 12-month interval or a LSIL in a 6-month interval As a pattern consistent with opportunistic screening programs some follow-up data were missing due to the absence of central regulatory coordination Identification was available only for cases with abnormal cytology and data were only available for positive colposcopies and their subsequent procedures (biopsy or ETZ; 217 known diagnoses among 584 colposcopy referrals) Data regarding negative colposcopy results or the total number of colposcopies performed were unavailable Data analyses were performed using the chi-squared teste, Fisher’s test, or t-test with StatsDirect statistical software 3.0 (Wirral, UK, www.statsdirect.com) P-values < 0.05 were considered significant The research group accessed electronic data from the health information system and created a spreadsheet for statistical analyses The dataset from this study will be safely stored following the principles of research ethics data may be made available by the corresponding author (juliotex@unicamp.br) upon request with justification Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries Estimate/2023 - Cancer Statistics. Brazil. Instituto Nacional de Cancer Jose Alencar Gomes da Silva (INCA). https://www.gov.br/inca/pt-br/assuntos/cancer/numeros (2023) The IARC perspective on cervical cancer screening Estimating the public health impact of a national guideline on cervical cancer screening: An audit study of a program in Campinas Cervical cancer registered in two developed regions from Brazil: Upper limit of reachable results from opportunistic screening Effect of screening on incidence of and mortality from cancer of cervix in England: Evaluation based on routinely collected statistics Impact of the introduction of organised screening for cervical cancer in Turin Italy: Cancer incidence by screening history 1992–98 Cervical cancer screening programs in Europe: The transition towards HPV vaccination and population-based HPV testing Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials Koliopoulos, G. et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst. Rev. 8, CD008587. https://doi.org/10.1002/14651858.CD008587.pub2 (2017) Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: A cost-effectiveness study protocol Vale, D. B. et al. Is the HPV test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PLoS ONE 16, e0251688. https://doi.org/10.1371/journal.pone.0251688 (2021) Teixeira, J. C. et al. Organization of cervical cancer screening with DNA-HPV testing impact on early-stage cancer detection: A population-based demonstration study in a Brazilian city. Lancet Reg. Health Am. 5, 100084. https://doi.org/10.1016/j.lana.2021.100084 (2021) Cervical cancer screening with DNA-HPV testing and precancerous lesions detection: A Brazilian population-based demonstration study Status of implementation and organization of cancer screening in the European Union member states—summary results from the second European screening report Effective screening programmes for cervical cancer in low- and middle-income developing countries Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test Disparities in time trends of cervical cancer mortality rates in Brazil Cervical screening: ESGO-EFC position paper of the European society of gynaecologic oncology (ESGO) and the european federation of colposcopy (EFC) IBGE National Health Survey. https://biblioteca.ibge.gov.br/visualizacao/livros/liv101748.pdf (2019) Seade Foundation, Portal de Estatisticas do Estado de Sao Paulo. Filtered by city “Indaiatuba”, year “2011–2019”, population “women”, and age-group “25 to 64 years”. http://produtos.seade.gov.br/produtos/projpop/index.php (2023) Coronavirus - Dados Completos. Governo do Estado de Sao Paulo. https://coronavirus.seade.gov.br (2023) In The Bethesda System for Reporting Cervical Cytology: Definitions Revised FIGO staging for carcinoma of the cervix uteri Download references This project was funded by the University of Campinas (Women’s Hospital) as detailed below: The study (screening program implementation and cost-effectiveness analysis) was designed by researchers from the University of Campinas and introduced by the Indaiatuba City Hall Both the University of Campinas and the municipality used the existing and functioning structure to implement the new screening program and carry out the study at no additional cost The supplies and equipment required to perform HPV testing were provided and/or supported by Roche Diagnostics No compensation or cash transfers were provided to any institution or researchers named in the cooperation agreement between the parties including manuscript writing and the decision to publish Michelle Garcia Discacciati & Luiz Carlos Zeferino and LZ coordinated the analysis and the development of this manuscript The authors declare no competing interests Some parts of this manuscript were derived from an academic master’s dissertation by I Polegatto under the tutorial of J Teixeira and submitted to the Postgraduate Program of Obstetrics and Gynecology from the University of Campinas Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Download citation DOI: https://doi.org/10.1038/s41598-024-71735-2 Anyone you share the following link with will be able to read this content: a shareable link is not currently available for this article Sign up for the Nature Briefing newsletter — what matters in science for the 43rd Brazilian National Arabian Horse Show from July 3 to 8 Owners from Qatar and Saudi Arabia will join São Paulo – The 43rd Brazilian National Arabian Horse Show will be held in Indaiatuba and bring in BRL 10 million (roughly USD 2 million) According to information from the Brazilian Association of Arabian Horse Breeders (ABCCA) the event will feature 320 breed animals and be attended by participants from Brazil There will be events of Conformation (Halter) and Performance (Western Pleasure and its body proportions in relation to each other while performance events take into account riding styles The show will host halter and performance events of the Brazil Cup and the South American round of the Emirates Arabian Horse Global Cup Championship judges hail from across Brazil The show will feature awards and two auctions of animals from certified breeders the institution has invested nearly BRL 2.2 million (USD 400,000) in the event “We’re expecting a record-high number of horses and a record turnout as well as a heavy presence of foreign breeders,” the association’s president The 43rd Brazilian National Arabian Horse Show will be broadcast online. Admission is free. Find out more at https://nacional.abcca.com.br/pt Read more:São Paulo to host Arabian horse show The Gulf country has deposited its instrument of acceptance of the World Trade Organisation (WTO) Agreement on Fisheries Subsidies which is aimed at curbing harmful subsidies that contribute to overfishing and promoting the sustainable management of global marine resources The Brazil-Arab News Agency (ANBA) is the news website of the Arab Brazilian Chamber of Commerce Its goal is to promote communication between Brazilians and Arabs Connecting decision makers to a dynamic network of information Bloomberg quickly and accurately delivers business and financial information 2024 at 9:50 AM ESTBookmarkSaveInflation smashed through the top of the central bank’s tolerance range in Brazil and accelerated much more than expected in Chile as surging energy costs give policymakers another reason to worry Metrics details The causal relationship between high-risk (hr) HPV infection and precancerous lesions or cervical cancer has led to the development of strategies to increase screening performance and prevent this cancer The increased sensitivity of DNA-HPV testing compared to cervical cytology favors DNA-HPV testing as a primary screening test and this cancer remains a considerable health problem with a high proportion of diagnoses in advanced stages This paper aims to describe the design and implementation of the Cervical Cancer Screening Program with primary DNA-HPV testing (CCSP-HPV) planned for Indaiatuba City (SP) Brazil; the strategies to achieve higher population coverage; and a study protocol for cost-effectiveness analyses The CCSP-HPV was designed based on successful guidelines that replaced cervical cytology-based screening by the DNA-HPV test performed at 5-year intervals The screening will be performed for the female population aged 25-64 years cared for by the public health system and aim to reach 80% coverage after completing the first round The chosen DNA-HPV test detects 14 hr-HPV types and genotypes HPV-16 and 18 All women with a negative test will be reassessed after five years Women showing a positive test for HPV-16 and/or 18 will be referred for colposcopy Those showing the other 12 hr-HPV types will be tested by cytology The histopathologic evaluation will be reviewed by a pathologist panel and aided by p16 immunohistochemistry A cost-effectiveness analysis will be performed by a Markov model comparing the cost of the new program and the screening performed by conventional cytology five years prior (2011–2016) The new screening program is considered a breakthrough for public health regarding cervical cancer which is the third leading cause of cancer death among Brazilian women Achieving at least 80% coverage will have the possibility to change this scenario The proposed program will provide a modern cervical cancer screening method for women and information about cost-effectiveness will help other similar places support the decision of implementing cervical cancer screening using the DNA-HPV test These factors promote the search for alternative strategies These factors highlight the need for reassessment of the cervical cancer screening program currently in place in Brazil was the pioneer in Brazil deciding to replace cervical cytology with the primary DNA-HPV test for primary cervical cancer screening This paper aims to describe the implementation of the Cervical Cancer Screening Program with Primary DNA-HPV testing (CCSP-HPV) the strategies designed to reach higher population coverage and a study protocol for the cost-effectiveness analyses The target women are women relying only on public health services (SUS – Unified Health System) and candidates for cervical cancer screening Cervical cancer screening in Brazil includes women aged 25-64 years health care is free of charge to every citizen although some people co-use private services around 50% of the female population uses private services and the other half relies exclusively on the SUS to access health care the target SUS population was 31,681women for the new program As the goal of the program is to reach at least 80% coverage of the target population after five years the population of the study was estimated to be 25,000 women in five years which means at least 5000 women tested per year The organization of the CCSP-HPV implies developing strategies to reach higher target population coverage evaluate the compliance of the staff to the program and research to evaluate the cost-effectiveness a similar population from the same city that performed routine cytology screening from 2012 to 2016 five years before CCSP-HPV will be the reference for comparison of cost-effectiveness evaluation This reference population (years 2012–2016) performed nine to eleven thousand pap tests per year (total 54,000 to 66,000 tests) with the official recommendations for pap screening women have started sexual activity aged 25 to 64 years are the target for regular screening test (women over 64 years will be permitted for a single exit test by personal request); women physically well enough to undergo a pelvic exam The inclusion criteria evaluation should be postponed if any of the following conditions are met: 40 days postpartum period cervicovaginal infection and having underwent the last cervical cytology in the last 12 months women who have already undergone DNA-HPV testing for different medical purposes except screening; women with a previous diagnosis of the cervical lesion followed in specialized clinics; All women from Indaiatuba that underwent cytology tests by SUS from 2012 to 2016 These women will be identified from the regional central laboratory database located at the Cytopathology Laboratory of Women’s Hospital (University of Campinas - UNICAMP) All information about the compliance of the staff to follow the official recommendations related to conducting the women with abnormal pap are available at Colposcopy Unit in Indaiatuba City and Women’s Hospital (UNICAMP) Overview of cervical cancer screening guidelines using a primary DNA-HPV test with HPV-16 and 18 genotyping in Indaiatuba City (SP) the Cobas® HPV Test will be performed in a central laboratory the Laboratory of Women’s Hospital (HPV Test Lab) located at the University of Campinas (UNICAMP) The Cobas® HPV Test runs on the advanced Cobas® 4800 System (Roche Molecular Systems Women with negative DNA-HPV tests will be instructed to return after five years to repeat the test Women who test positive for HPV-16 and/or 18 will be referred for colposcopy Women positive for the other 12 h-HPV types will also be evaluated by cervical cytology performed in the same sample women will return after 12 months to repeat the DNA-HPV test If any abnormality was detected in cytology (ASC-US suspicious for glandular lesion or cancer) The collection of cervical samples will be performed in the routine of care at 18 primary health care units in Indaiatuba The cervical sample will be collected using a brush and the sample will be stored in a previously identified vial containing preservative medium specific for the HPV test (PreservCyt All procedures related to sample collection and transportation to the HPV testing laboratory are similar to those used in previous cytology screening except for sample slides (conventional cytology) replaced for liquid-based cytology (LBC) vials All primary health care units will be informed about CCSP-HPV guidelines on the collection which will be primarily sent to a central unit in the city and from there to the HPV testing laboratory This sample transport is planned to take place within one week The samples can be well kept for up to 6 weeks at room temperature of 15 to 30 degrees Celsius In cases of positive tests for the other 12 hr-HPV types the cytology evaluation and results will follow the Bethesda System Classification 2014 Considering that cervical cytology has a very variable sensitivity for the detection of HSIL the cytologists will have prior information on HPV results (tested positive for other 12 hr-HPV types) The strategy is to increase attention to the smallest morphological details and thus increase the sensitivity of the cytology test The cervical biopsy will be guided for colposcopy using biopsy surgical tweezers to take a tissue sample from the suspected area of cervical epithelium Surgical procedures for excision of the transformation zone (EZT) will be performed for diagnostic purposes in women with or suspected HSIL EZT will be performed using a loop electrosurgical procedure in the same colposcopy unit the surgical procedure in the cervix will be performed at City Hospital and The Women’s Hospital (UNICAMP) is the reference for more comprehensive support for cervical cancer cases if it occurs in the current organization The endpoints of this study protocol include age compliance of the CCSP-HPV the coverage rate of the target population and cervical lesions identified and treated These data will be included in cost-effectiveness analyses based on appropriate and specific endpoints Women’s information and test results will be entered into a single Excel database for the entire municipality Some information will also be present in the Integrated Health Informatics System of Indaiatuba (SALUS System) which is a health management system for the entire city A more detailed information system for monitoring screening population management according to the flowchart proposed for the CCSP-HPV protocol (schedule for sample collection including follow-up cervical cytology and/or colposcopy which will be integrated into the SALUS System Information will be discriminated for every primary health care unit we will have the opportunity to monitor and identify areas with adequate population coverage and areas that need further action to achieve adequate coverage The databases with information generated from this protocol will be revised and analyzed annually and after the study ends During the five years planned for the study women inclusion and additional health procedures for those with positive HPV testing will be monitored every 30 days A cost-effectiveness survey is planned for this study and it will be compared with the screening performed by conventional cervical cytology five years prior Such analysis will also consider the diagnostic rates of precursor lesions and cervical cancer corresponding to the HPV test or cervical cytology-based periods Indaiatuba public health system and regional health service (Women’s Hospital UNICAMP) records will be reviewed looking for cases of HSIL AIS or cervical cancer diagnosed and managed out of the screening set in women from Indaiatuba and the detailed process will be subject to future publication Cost information regarding the screening process will be collected for the previous cytology screening and during the implementation of the new program Qualitative analysis is also foreseen to evaluate the perception of the population and health professionals regarding the modification of the method of cervical cancer screening in the city The mayor of Indaiatuba City approved a law in 2017 replacing standard cytology for screening by HPV test in all Public Health Care System and the CCSP-HPV became a standard of care The Ethics Committee of UNICAMP approved the study protocol (number 1045580 2015) to evaluate CCSP-HPV implementation and cost-effectiveness The Ethics Committee also approved the waiver of the Informed Consent Form considering that this study will analyze data from health system records with a considerable perspective for improving health care offered to the population These new actions may change the current scenario regarding cervical cancer in Brazil where one woman dies every 90 min at a mean age of 45 years suggesting that over two-thirds of the women are out of date or out of the regular screening the new screening program proposed for Indaiatuba City will ensure an additional identification of 50% of women who have not had regular preventive exams before This opportunity will correct a health system distortion that neglects women without periodic preventive tests starting to use a modern method that requires fewer evaluations in their lives countering and improving a possible lower specificity of DNA-HPV testing in young people The protocol proposed will evaluate the performance of CCSP-HPV in women aged 25-29 years compared to older women Health managers agreed with the strategy to have one test available for screening and to simplify the flowchart and decided to eliminate cervical cytology from primary health clinics after the introduction of the DNA-HPV test This is the main decision to prevent the possibility of health professionals performing both HPV-DNA tests and cytology for screening purposes The CCSP-HPV program started in October 2017 and DNA-HPV testing was introduced at the same time in all primary health care units from SUS 99.1% in women within the target age group (25-64 years) well above the planned five thousand tests per year and the next steps are pretest of the cost-effectiveness model built in a real scenario analyze the coverage results achieved after two years the prevalence of positive tests by HPV type and age group outcome according to the program flowchart and the first interim analyses of the cost-effectiveness of the program Moving from opportunistic to organized screening has been a challenge including for the most developed countries This fact could be partially attributed to the habit and culture of professionals and women who adopted annual testing with cytological examination as the standard to be followed despite the recommendations establishing longer intervals The introduction of HPV testing as a primary screening method can break with this cultural practice based on the annual routine cytological examination allowing or facilitating the establishment of a new practice now a five-year interval based on scientific evidence Avoiding overtesting due to repetition at shorter intervals saves money and provides resources to invest in increasing population coverage without the need for additional investments beyond those for the active search for women who are not compliant with the cervical cancer screening data may be made available by the corresponding author upon request with justification The results of this study will be disseminated through publications in journals presentation of abstracts in scientific congresses and meetings with public health managers Atypical squamous-cells of undetermined significance Cervical Cancer Screening Program with primary DNA-HPV testing High-grade squamous intraepithelial lesion Sistema Unico de Saude (Public Health System from Brazil) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries BRASIL, Ministério da Saúde, Instituto Nacional do Câncer-INCA. In: Números do Câncer. 2019. https://www.inca.gov.br/numeros-de-cancer Cytological screening for cervical cancer prevention Alternative approaches to cervical cancer screening for developing countries HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica and risk for cervical neoplasia: a 10-year cohort analysis Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials: international HPV screening working group Comparison of cervical cancer screening strategies incorporating different combinations of cytology and genotyping for HPV 16/18: results from the ATHENA HPV study Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing Primary human papillomavirus testing in organized cervical screening U.S. Food and Drug Administration, Premarket Approval (PMA). In: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100020 Accessed 25 NOV 2019 Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance Brasil, Ministério da Saúde, Instituto Nacional do Câncer- INCA. Available in: https://www.inca.gov.br/numeros-de-cancer Estimating the public health impact of a national guideline on cervical cancer screening: an audit study of a program in Campinas Cervical Cancer registered in two developed regions from Brazil: upper limit of reachable results from opportunistic screening Vale DB, Sauvaget C, Muwonge R, Thuler LCS, Basu P, Zeferino LC, Sankaranarayanan R. Level of human development is associated with cervical cancer stage at diagnosis. J Obstet Gynaecol. 2019;39(1):86–90. https://doi.org/10.1080/01443615.2018.1463976 Epub 2018 Sep 19 Atlas of Human Development in Brasil, Indaiatuba, SP. The Municipal Human Development Index (MHDI). In: http://www.atlasbrasil.org.br/2013/en/perfil_m/indaiatuba_sp Seade Foundation, Porta de Estatísticas do Estado de Sao Paulo. Filtered by city “Indaiatuba”, the year “2014”, population “women”, and age group “25 to 64 year”. In: http://produtos.seade.gov.br/produtos/projpop/index.php Retrospective international survey and HPV time trends study group Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice International Federation of Cervical Pathology and Colposcopy (IFCPC). In: Terminologia colposcopica do colo uterino. http://www.ifcpc.org/images/docs/nomenportug.pdf Histological typing of female genital tract tumours [World Health Organization International histological classification of Tumours] The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial Excessive pap smears due to opportunistic cervical cancer screening Download references This project is funded by UNICAMP (Women’s Hospital) as detailed below: This study proposal (screening program implementation and cost-effectiveness analyses) was designed by researchers from UNICAMP and introduced by the Indaiatuba City Hall Both UNICAMP and the municipality will use the existing and functioning structure to place the new screening program and carry out the proposed study at no additional cost The supplies and equipment required to perform HPV testing (for one round in five years) and a screening program coordinator are being provided or supported by Roche Diagnostics Roche Diagnostics supports an external statistician defined by researchers to develop a model and perform the planned cost-effectiveness analyses There are no planned compensations or cash transfers provided to any institution or researchers stated in the cooperation agreement between the parties Division of Gynecologic and Breast Oncology All authors reviewed the final version of the study protocol and LZ coordinated the development of this manuscript and all authors have the opportunity to review The author(s) read and approved the final manuscript a law in the city of Indaiatuba that replaces conventional cytology by the DNA-HPV test for cervical cancer screening was approved The UNICAMP Ethics Committee approved the study protocol (number 1,045,580 2015) to evaluate the implementation and cost-effectiveness of CCSP-HPV Roche Diagnostics reviewed the study protocol before deciding to participate and to provide financial support for some activities of this study including its HPV test chosen for the screening program The authors have no other competing interests to declare unless otherwise stated in a credit line to the data Download citation DOI: https://doi.org/10.1186/s12889-020-08688-4 Unilever GlobalChange location At a glance We are a global consumer goods business with strong fundamentals and differentiated capabilities Our strategy Our strategy begins with a purpose that places consumers at the heart of everything we do: Brighten everyday life for all Our leadership Our international leadership team drives our company Innovation and R&D at Unilever Innovation is at the heart of everything we do within R&D at Unilever. Press and media See the very latest from our press desk Sign up for alerts from Unilever Be the first to hear about our press releases, features and articles. our brands are meeting consumers’ daily needs from household staples to premium indulgence What's in our products? Discover the ingredients in our home, beauty and personal care products. Nature We’re committed to contributing to the protection and regeneration of nature Plastics Given the size of the plastics challenge we’re using our innovation capabilities to find new Livelihoods We’re working to improve the livelihoods of people in our global value chain Responsible business Our progress and reporting on issues such as human rights, equity, diversity and inclusion and safety. Partner to Win Our Partner to Win programme is taking our partnerships to a whole new level Our people plans Together with our partners we’re helping to provide decent livelihoods and supporting inclusive economic growth Supplier Climate Programme We're collaborating with key suppliers to reduce emissions from raw materials, ingredients and packaging by 2030, which will help us progress towards our net zero ambition. We’re on an exciting journey to transform our manufacturing approach with the global roll-out of a refreshed digital model streamlining operations and providing an essential catalyst to deliver our strategy Our Unilever Manufacturing System has helped further improve Overall Equipment Effectiveness at our Indaiatuba factory in Brazil increasing capacity by 20% and delivering €3 million in savings Our Heilbronn site in Germany reduced waste by 55% in 2024 while our Sikeston factory in the US contributed 28.5% of the total waste net impact across all our manufacturing sites in 2024 Our Cavite factory in the Philippines improved productivity from 51% in 2023 to 66% by the end of 2024 we’ve always had a strong focus on continuous improvement and operational excellence This was formalised in 2013 when we adopted the World Class Manufacturing (WCM) framework But our business and the markets in which we operate are changing fast So we’ve taken things to a whole new level with the roll-out of the Unilever Manufacturing System (UMS) it was developed through the collaboration of supply chain and digital and technology expertise to transform the way our factories operate The digitally enabled system helps factory teams consistently drive improvement integrate technology and optimise operations while also supporting them to develop strategic plans that align with business priorities Manufacturing presents one of the biggest areas of opportunity for the business to unlock efficiencies and drive productivity further From increasing production capacity and Overall Equipment Effectiveness (OEE) to reducing waste and improving energy efficiency it’s where our factories can make a huge contribution OEE is how we track operational efficiency and net productivity improvement A high OEE means our equipment is running at maximum potential This not only boosts factory performance but also contributes to the wider business by lowering costs increasing profitability and improving overall competitiveness That’s 2,100 manufacturing lines covering over 75% of our total production capacity across all factories where it has been deployed 5% in labour productivity and 8% cost savings “Training over 23,000 factory colleagues in digital skills and ownership across all functions and capabilities has been essential in the roll-out,” says Renato Miatello agile supply chain and it is an essential catalyst for landing our GAP 2030 strategy – delivering faster growth through driving productivity and simplicity Here are four examples of how UMS is making an impact in our factories Our Indaiatuba site in Brazil is the largest laundry detergent powder factory in the world and one of Unilever’s eight World Economic Forum Lighthouse sites recognised for applying advanced digital tech to work smarter it has had the highest OEE across Unilever for the last two years This means it can increase production in response to spikes in demand without the need to add new lines It can also mitigate the impact on costs by better utilising assets if volumes change Indaiatuba improved OEE by 85% and increased capacity by 20% all while delivering almost €3 million in savings says: “UMS gives us a high degree of agility to respond to fluctuations in demand And the savings it’s delivering are critical to remaining competitive as a production site.” At our Knorr production site in Heilbronn Germany Although a small percentage of total output representing both a financial loss and an inefficient use of resources Both resulted in the packs being rejected from the line However, thanks to rework machines untouched food can now be hygienically removed and repackaged analyse and visualise thousands of data points which are then digitalised onto a waste dashboard that the team can use to address any issues immediately waste was reduced by 55% in 2024 (compared with 2023) resulting in over €1.24 million net savings Sikeston is our largest Ice Cream factory by volume producing some of our biggest ice cream brands Despite reducing their raw material and production material (RMPM) waste to the optimal benchmark of 2.8% in 2023 the team took significant steps to further reduce waste in 2024 Their aim was to put in place processes that tracked and stopped waste at source Machine efficiency was identified as one of the key areas that needed improvement Through structured governance and UMS tools Sikeston reduced their RMPM waste by 32.5% in 2024 (compared to 2023) decreasing their total waste to a record 1.9% This significant milestone resulted in Sikeston contributing 28.5% of the total waste net impact (€3 million in savings) across all our manufacturing sites in 2024 Our Beauty & Wellbeing and Personal Care factory in the Philippines produces market-leading haircare products from Sunsilk and Creamsilk Using the UMS model to identify and prioritise areas that would yield the biggest wins in terms of efficiency and process improvements the team was able to quickly ramp up performance from 51% OEE in 2023 to 66% by the end of 2024 the team has boosted productivity in alignment with benchmark standards and delivered annual savings of over €250,000 Renato concludes: “Our manufacturing team is setting up to win and I’m confident we have the right formula UMS not only strives for excellence in manufacturing but is also pragmatic to apply It is a key driver of our growth ambition and we’re continuously updating the framework to further unlock efficiencies and maximise net productivity gains.” Unilever Philippines scales personal care production by 15% with powerhouse factory29 September 2023 Unilever Philippines has opened a production powerhouse in Cavite for its Beauty & Wellbeing and Personal Care businesses The €80 million investment will see the factory’s production ramped up by 15% increasing local jobs and serving accelerating demand in the region 5 ways we’re fighting factory food waste with teamwork and technology28 September 2023 On International Day of Awareness of Food Loss and Waste we check in with our factory frontline for the latest progress report on our fight against food waste Unilever sites join network of world’s most digitally advanced factories13 January 2023 Two more of our factories – in Tianjin, China and Indaiatuba, Brazil – have been awarded Lighthouse status by the World Economic Forum. This recognises how they are integrating the latest technologies to increase productivity and efficiency, and take care of the environment. We're always looking to connect with those who share an interest in a sustainable future. Get in touch with Unilever PLC and specialist teams in our headquarters, or find contacts around the world. AbilityNet (()=>{var e=async t=>{await(await t())()};(self.Astro||(self.Astro={})).load=e;window.dispatchEvent(new Event("astro:load"));})(); Have you got a few minutes to complete a survey We would love to hear about your experience using Unilever.com male mosquitoes were released that expressed a gene that meant their female offspring By Miriam Fauzia The biotechnology firm Oxitec has launched boxes containing genetically modified male mosquitoes of the species Aedes aegypti The release of genetically modified male mosquitoes into a city in Brazil temporarily cut the virus-carrying insects by up to 96 per cent. Although not a permanent fix, periodically releasing such mosquitoes could reduce the burden of infections including dengue, malaria and Zika Kevin Gorman at the biotechnology firm Oxitec in Abingdon, UK, and his colleagues are particularly looking to control dengue. Although usually mild, the infection can be fatal. Already widespread in many parts of the world, climate change… Explore the latest news, articles and features excavators and wheel loaders for the Brazilian market Customers in Brazil have utilized John Deere agriculture equipment for over 60 years and the expansion marks a significant investment in the company’s construction business in the market “As one of the fastest growing construction equipment markets in the world Brazil offers a great opportunity for John Deere Construction equipment,” said Michael Mack “The investment potential on infrastructure is very high in Brazil which makes us confident in the success of this enterprise.” Together with Hitachi Construction Machinery, John Deere invested approximately $180 million to build two manufacturing facilities that will meet the needs of the established John Deere dealer network that covers almost 90% of the Brazilian market The project broke ground in December 2011 and was completed in a little over two years “What differentiates John Deere in Brazil is the commitment to actively listen to customer feedback and use it in product development,” said Roberto Marques “We aim to maintain a close relationship with our customers using a highly qualified dealer network that’s always prepared to offer prompt service.” Models that will be produced in John Deere’s exclusive plant include: Backhoe Loader: 310K Wheel Loaders: 524K Models that will be produced in the excavator plant in partnership with Hitachi include: John Deere Excavators: 160G, 180G, 210G, 250G, 350G "The opening represents great advancements for our operations in Brazil,” said Michijiro Kikawa, chairman of the board, Hitachi Construction Machinery Corporation. “John Deere and Hitachi have a solid partnership, placing us at the forefront of the hydraulic excavator market." All John Deere equipment manufactured in Brazil will come standard with John Deere WorkSight, a comprehensive, easy-to-use suite of technology available for increasing uptime and productivity while lowering operating costs. John Deere will continue to import three crawler dozer models and two motor graders to the Brazil market. Lenovo has reorganized its operations in Brazil as part of a plan to reduce spending The Chinese company has swapped a manufacturing facility of 52,000 square meters in the São Paulo state city of Itu for a facility that is half the size in Indaiatuba The workforce has also been reduced from 5,000 staff in Brazil to 800 employees this was necessary to "adapt costs to a new market reality." "The upside is that the market has remained at about the same size for the last three quarters and we believe that the decline is over," Lenovo Brazil's president of the computer division "Everyone has been hurt [by the recession] and has been adopting a conservative purchasing behavior but despite the crisis we have seen over the last few years it is only a matter of time until the country gets back to being one of the top markets in the world for electronic items," the executive added About 90 percent of Lenovo items sold in Brazil are produced in the company's facility in Indaiatuba which has capacity for manufacturing 1 million items yearly More expensive items such as notebook Yoga 910 are imported from China and the United States The Chinese manufacturer currently ranks third in the Brazilian PC market with market share of 13 percent, behind Dell and HP Back in 2012, Lenovo bought Brazilian consumer electronics firm CCE to increase its market share in the country the Chinese firm courted other local manufacturers Lenovo then sold CCE back to its original owners for an undisclosed sum last year The company said it had decided to focus on "value-added products" such as its smartphone business and its premium range of PCs and servers According to IDC, the Brazilian market for PC sales has seen a new low in the third quarter of 2016 with a 35 percent decline in relation to the same period a year ago and 11 percent down on the second quarter The analyst has no forecast for improvement in the coming months Parece que a página que você está procurando não está disponível Don't have an account? Subscribe “Our goal is to help stakeholders understand the future of mobility.” Home › News Releases › Toyoda Gosei Announces Capital Investment in Pecval Industria Ltda. a Plastic Automotive Parts Supplier in Brazil will purchase a stake in plastic auto parts maker Pecval Industria Ltda a producer of plastic interior and exterior parts for automobiles This will strengthen Toyoda Gosei’s business foundation in the growing market of Brazil Pecval is a wholly owned subsidiary of Shimizu Industry Co. Shimizu Industry is a subsidiary of Denso Corporation [equity stake 54%]) Toyoda Gosei will acquire equity in Pecval from Shimizu Industry after completing the necessary procedures The capital investment is scheduled for October 2015 and will give Toyoda Gosei a 30% equity stake Toyoda Gosei will be able to supply automakers from two production locations in Brazil: Pecval and GDBR Industria e Comercio de Componentes Quimicos e de Borracha Ltda a Toyoda Gosei subsidiary that began production in December 2014 Let us help you understand the future of mobility Δdocument.getElementById( "ak_js_1" ).setAttribute( "value" and trends shaping the future of electric mobility Tickets for this in-person event are limited and trends shaping the future of the software-defined vehicle and trends shaping the future of autonomous mobility